facebook button ZN-e4 for Patients with an EGFR Mutation
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

ZN-e4 for Patients with an EGFR Mutation

Sponsor: Zeno Pharmaceuticals, Inc.

Protocol ZN-e4-001: A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations